[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrial-septal-defect\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrial-septal-defect":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,42,72,95,126,153,174,195,216],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100507462","lifetech-ceraflex-asd-closure-system-post-market-clinical-follow-up-100507462",false,"NCT05887700","Lifetech CeraFlex™ ASD Closure System Post-Market Clinical Follow-Up","A Multi-center, Single-arm, Real-world Registry Assessing the Clinical Use of the Lifetech CeraFlex™ ASD Closure System","Inclusion Criteria:\n\n1. Patients with a confirmed diagnosis of Atrial Septal Defect (ASD) and implanted with the investigational device as per IFU instructions.\n2. Patients or legally authorized representatives have signed Data Release Consent or equivalent documents.\n\nExclusion Criteria:\n\nPatients did not conduct any follow up visit after hospital discharge.","ALL",{"count":18,"type":19},145,"ESTIMATED","OBSERVATIONAL","The objective of this post-market registry is to assess the clinical use of the Lifetech CeraFlex™ Closure System in a real-world and on-label fashion.",[23],"Atrial Septal Defect",[25,23,26,27,28],"Lifetech","ASD","CeraFlex","ASD Closure System","RECRUITING","2026-05-21",{"date":32,"type":33},"2026-05-26","ACTUAL",{"date":35,"type":33},"2024-07-09",{"date":37,"type":19},"2027-06-30",{"name":39,"class":40},"Lifetech Scientific (Shenzhen) Co., Ltd.","INDUSTRY",5,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":20,"phases":4,"briefSummary":52,"conditions":53,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100635406","hummingbird-ice-study-100635406","NCT07552272","Hummingbird ICE Study","Inclusion Criteria:\n\n* 18 years of age\n* Willing to provide written, dated and signed, informed consent\n* Undergoing percutaneous cardiac intervention procedures in with VeriSight Pro is used\n\nExclusion Criteria:\n\n* Contraindicated for ICE catheter placement or considerations that make placement of VeriSight not technically feasible\n* Known contraindicated conditions include sepsis, major coagulation abnormalities, presence of any intracardiac thrombus, presence of class IV angina or heart failure, deep vein thrombosis, or significant peripheral vascular disease","18 Years",{"count":50,"type":19},1000,"2 Days","The goals of this observational study are to collect data and ultrasound images using the Philips VeriSight Pro intracardiac echocardiography (ICE) catheter to assess safety and effectiveness and to support development efforts of the VeriSight Pro imaging platform.",[54,55,56,23,57,58],"ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION","Atrial Fibrillation (AF)","Valve Disease, Heart","Patent Foramen Ovale","Tricuspid Valve Disease",[60,61],"Intracardiac Echocardiography (ICE)","VeriSight","NOT_YET_RECRUITING","2026-05-18",{"date":65,"type":33},"2026-05-22",{"date":67,"type":19},"2026-07",{"date":69,"type":19},"2031-07",{"name":71,"class":40},"Philips Clinical & Medical Affairs Global",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100633618","safety-and-efficacy-of-the-absnowtm-ii-absorbable-atrial-septal-defect-closure-system-for-atrial-septal-defect-closure-therapy-100633618","NCT07529028","Safety and Efficacy of the AbsnowTM II Absorbable Atrial Septal Defect Closure System for Atrial Septal Defect Closure Therapy","A Prospective, Multicenter, Randomized Controlled, Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of the AbsnowTM II Absorbable Atrial Septal Defect Occluder System for Atrial Septal Defect Closure Therapy","Inclusion Criteria:\n\n1. Aged≥3years, body weight≥10 kg, regardless of gender;\n2. Patients with secundum atrial septal defect (ASD) with left-to-right shunt and evidence of right ventricular volume overload (echocardiography indicating right ventricular enlargement);\n3. ASD diameter≥5 mm and\\\u003C26 mm;\n4. The distance from the ASD rim to the openings of the superior\u002Finferior vena cava and pulmonary veins≥5mm, and the distance to the atrioventricular valve≥7mm;\n5. Patients who can understand the trial purpose, voluntarily participate and sign the informed consent form, and are willing to cooperate with follow-up completion.\n\nExclusion Criteria:\n\n1. Primum, sinus venosus, and unroofed coronary sinus types of atrial septal defect (ASD);\n2. Patients with ASD diameter≥26 mm;\n3. Combined with other structural heart diseases requiring treatment besides ASD;\n4. Complicated with severe pulmonary hypertension or Eisenmenger syndrome;\n5. Patients who suffered from infectious diseases within 1 month before enrollment, including infective endocarditis, or those with uncontrolled infectious diseases;\n6. Patients who suffered from hemolysis, hemorrhagic diseases, unhealed peptic ulcer within 1 month before enrollment, or have any contraindications to aspirin therapy (except those who can take other antiplatelet drugs continuously for 6 months);\n7. Intracardiac thrombus detected by echocardiography (especially thrombus in the left atrium or left atrial appendage), or venous thrombosis at the catheter insertion site;\n8. Patients allergic to the materials of the investigational medical device;\n9. Pregnant or lactating females, or those who plan to have children during the trial and are unwilling to adopt effective contraceptive measures;\n10. Patients who participated in other drug or medical device clinical trials before enrollment and have not reached the primary endpoint;\n11. Patients with other factors deemed inappropriate to participate in this clinical trial by the investigator.","3 Years",{"count":81,"type":19},236,"INTERVENTIONAL",[84],"NA","A prospective, multicenter, randomized controlled, non-inferiority clinical trial to evaluate the safety and efficacy of the AbsnowTM II absorbable atrial septal defect occluder system for atrial septal defect closure therapy. A parallel controlled comparison will be conducted using the Cera atrial septal defect occluder manufactured by the same company as the control device, to evaluate the safety and efficacy of the AbsnowTM II absorbable ASD occluder system in the treatment of ASD occlusion.",[23],"2026-04-07",{"date":89,"type":33},"2026-04-14",{"date":91,"type":19},"2026-04",{"date":93,"type":19},"2031-12",{"name":39,"class":40},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":16,"minAge":48,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":105,"conditions":106,"keywords":111,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":125},"100615460","a-multicenter-study-on-the-normal-reference-range-and-clinical-significance-of-the-right-atrioventricular-coupling-index-assessed-by-artificial-intelligence-based-three-dimensional-echocardiography-100615460","NCT07292896","A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography","Healthy Adults Group\n\nInclusion Criteria:\n\n* Participants must meet all of the following criteria to be enrolled:\n\n  1. Of Han Chinese ethnicity\n  2. Aged 18-79 years\n  3. Normal blood pressure (\\\u003C 140\u002F90 mmHg)\n  4. Normal fasting blood glucose\n  5. Normal blood lipid levels (triglycerides, total cholesterol, low-density lipoprotein, high-density lipoprotein)\n  6. Normal complete blood count results (hemoglobin concentration, white blood cell count, red blood cell count, platelet count)\n  7. Normal liver and renal function (alanine transaminase \\\u003C 2× upper limit of normal; normal creatinine and blood urea nitrogen)\n  8. Normal electrocardiogram results (occasional atrial premature beats may be enrolled at the investigator's discretion)\n  9. No structural heart disease and normal cardiac function confirmed by echocardiography\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet any of the following criteria:\n\n1. Clinically significant cardiac valve regurgitation (≥ mild severity)\n2. Respiratory diseases: acute or chronic respiratory disorders\n3. Endocrine diseases: thyroid disease, diabetes mellitus, hyperaldosteronism, pheochromocytoma, etc.\n4. Abnormal liver function (alanine transaminase \\> 2× upper limit of normal), abnormal renal function (elevated creatinine beyond normal range), or dyslipidemia (elevated triglycerides, total cholesterol, low-density lipoprotein, or high-density lipoprotein)\n5. Other systemic diseases: anemia, malignancy, connective tissue disease, large artery\u002Fperipheral vascular diseases (aortic dilation, aortic dissection, coarctation of the aorta, Takayasu arteritis, atherosclerosis), etc.\n6. Pregnant or lactating women\n7. Professional athletes\n8. Poor-quality ultrasound images that cannot support parameter measurement and analysis\n\nPulmonary Hypertension Group\n\nInclusion Criteria:\n\nPatients must meet all of the following criteria to be enrolled:\n\n1. Aged 18-79 years\n2. Confirmed diagnosis via right heart catheterization: mean pulmonary arterial pressure (mPAP) ≥ 20 mmHg, in accordance with the 2022 ESC\u002FERS guidelines\n\nExclusion Criteria:\n\nPatients will be excluded if they meet any of the following criteria:\n\n1. Unable to complete right heart catheterization or pressure-volume loop assessment\n2. Complicated with significant left heart disease (left ventricular ejection fraction \\[LVEF\\] \\\u003C 50%, significant mitral valve disease)\n3. Pericardial disease or arrhythmias (e.g., atrial fibrillation) that severely impair right heart function evaluation\n4. Poor-quality images that prevent accurate measurement of right atrial or right ventricular parameters\n5. Concurrent liver or renal disease\n6. Concurrent malignancy\n7. History of surgical procedures such as pulmonary endarterectomy or balloon pulmonary angioplasty\n\nHeart Failure Group\n\nInclusion Criteria:\n\nPatients must meet all of the following criteria to be enrolled:\n\n1. Aged 18-79 years\n2. Meets the 2022 AHA\u002FACC\u002FHFSA diagnostic criteria for heart failure\n\nExclusion Criteria:\n\nPatients will be excluded if they meet any of the following criteria:\n\n1.Complicated with significant valvular heart disease (e.g., severe mitral regurgitation, severe tricuspid regurgitation, etc.)\n\nTricuspid Regurgitation Group\n\nInclusion Criteria:\n\nPatients must meet all of the following criteria to be enrolled:\n\n1. Moderate or severe primary or secondary tricuspid regurgitation confirmed by echocardiography\n2. Aged 18-79 years\n\nExclusion Criteria:\n\nPatients will be excluded if they meet any of the following criteria:\n\n1. Pericardial disease or arrhythmias (persistent atrial fibrillation) that interfere with measurements\n2. Congenital heart disease or residual lesions after surgical correction\n\nAtrial Septal Defect Group\n\nInclusion Criteria:\n\nPatients must meet all of the following criteria to be enrolled:\n\n1. Secundum atrial septal defect confirmed by echocardiography or transesophageal echocardiography\n2. Patients who have not undergone closure or surgical correction, or stable patients with \\> 3 months postoperatively\n3. Aged 18-79 years\n\nExclusion Criteria:\n\n1.Complicated with other complex congenital heart diseases.",true,"79 Years",{"count":104,"type":19},2640,"This multicenter study aims to establish the normal reference range of the Right Atrioventricular Coupling Index (RACI) in healthy Chinese adults using AI-based 3DE technology. It will also analyze the correlation between RACI and physiological parameters such as age, gender, and body surface area. Additionally, the study will explore the variation characteristics of RACI in patients with pulmonary hypertension, heart failure, tricuspid regurgitation, and atrial septal defect, and evaluate the clinical value of RACI in disease diagnosis, differential diagnosis, and risk stratification.",[107,108,109,110,23],"Healthy Adults","Pulmonary Hypertension","Tricuspid Regurgitation","Heart Failure",[112,113,114],"Right Atrioventricular Coupling Index","3D Echocardiography","AI-assisted Imaging","2025-12-06",{"date":117,"type":33},"2025-12-18",{"date":119,"type":19},"2025-12",{"date":121,"type":19},"2026-12",{"name":123,"class":124},"First Hospital of China Medical University","OTHER",25,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":152},"100542777","cerebral-microembolization-associated-with-pfo-closure-100542777","NCT06347276","Cerebral Microembolization Associated With PFO Closure","De Novo Cerebral Microembolization Associated With Patent Foramen Ovale Closure","PFO group\n\nInclusion Criteria:\n\n1\\) age 18 to 65 years; 2) documented PFO with medium-to-large shunts (≥ 20 microbubbles by c-TCD at rest or during the Valsalva maneuver); 3) history of embolic stroke (based on brain magnetic resonance imaging within 24 hours after symptom onset) or TIA within 6 months without other identifiable causes; 4) history of migraine for more than one year without other identifiable causes; 5) asymptomatic group: incidental finding of PFO in asymptomatic individuals, and presence of high-risk activities and\u002For anatomical features related to PFO (high-risk activities were defined as those in which the Valsalva maneuver was performed frequently or those that increased the risk of venous gas formation; and high-risk anatomical features included atrial septal aneurysm and\u002For curtain pattern on c-TCD).\n\nExclusion Criteria:\n\n1\\) presence of any known vascular risk factor, including hypertension, hypercholesterolemia, diabetes mellitus, atrial fibrillation, smoking and obesity; 2) history of embolic stroke or TIA within the past one month; 3) history of deep vein thrombosis or pulmonary embolism; 4) presence of coronary artery disease and carotid artery lesions; 5) presence of coexistent cardiovascular structural malformations or diseases; 6) allergy to contrast medium; 7) refusal to participate.\n\nASD group\n\nInclusion Criteria:\n\n1\\) age 18 to 65 years; 2) secundum ASD size 10 to 20 mm, with sufficient surrounding rims, except the aortic rim; 3) right heart catheterization: resting SPAP \\\u003C 50 mm Hg, Qp\u002FQs ≥ 1.5 and PVR \\\u003C 5 WU.\n\nExclusion Criteria:\n\n1\\) presence of any known vascular risk factor, including hypertension, hypercholesterolemia, diabetes mellitus, atrial fibrillation, smoking and obesity; 2) associated with other cardiac abnormalities or diseases; 3) resting SPAP ≥50 mm Hg and resting PVR ≥5 Wood units;4) primum or sinus venosus type ASD; 5) presence of intracardiac thrombi, permanent contraindications to platelet therapy, and allergic reaction to nickel.","65 Years",{"count":135,"type":19},800,"This study aims to investigate (1) the de novo cerebral microembolization in patients who undergo transcatheter closure of PFO or ASD, and (2) evaluate the relationship between de novo cerebral microembolization and in situ thrombus within PFO.",[138,23,139],"Thrombosis Cardiac","Patent Foramen Ovale (PFO)",[141],"Patent foramen ovale; stroke; migraine; thrombus","2025-07-20",{"date":144,"type":33},"2025-07-24",{"date":146,"type":33},"2024-01-01",{"date":148,"type":19},"2026-12-31",{"name":150,"class":151},"China National Center for Cardiovascular Diseases","OTHER_GOV",1,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},"100581386","cera-asd-occluder-post-market-clinical-follow-up-study-100581386","NCT06849635","Cera™ ASD Occluder Post-Market Clinical Follow-Up Study","Cera™ ASD Occluder Post-Market Clinical Follow-Up Study：A Multi-Center, Single-arm, Ambispective Post-Market Follow-Up Study","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of secundum Atrial Septal Defect (ASD).\n* Patients was implanted with the study device from 01 Jan 2020 to 31 Dec 2023 as per IFU instructions.\n* Patients or legally authorized representative are willing to the collection and processing of his\u002Fher data or sign the Informed Consent.\n\nExclusion Criteria:\n\n* Patients who have extensive congenital cardiac anomaly which can only be adequately repaired by cardiac surgery.\n* Patients who have sepsis within one month prior to implantation, or any systemic infection that can't be successfully treated prior to device placement.\n* Patients known to have a bleeding disorder, untreated ulcer or any other contraindications to aspirin therapy, unless another anti-platelet agent can be administered for 6 months.\n* Patients who have demonstrated intra-cardiac thrombi on echocardiography (especially left atrial or left atrial appendage thrombi).\n* Patients whose size (i.e., too small to tolerate TEE probe, catheter size, etc.) or condition (active infection, etc.) would cause the patient to be a poor candidate for cardiac catheterization.\n* Patients where the margins of the defect are less than 5mm from the coronary sinus, AV valves or right upper lobe pulmonary vein.\n* Patients did not conduct any follow up visit after hospital discharge.",{"count":161,"type":19},139,"The objective of this post-market study is to:\n\n* collect real-word clinical data and confirm the long-time safety and performance of the Lifetech Cera™ ASD Occluder\n* identify previously unknown side-effects",[23],[23],"2025-03-03",{"date":167,"type":33},"2025-03-06",{"date":169,"type":33},"2025-01-03",{"date":171,"type":19},"2026-02-28",{"name":39,"class":40},6,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":4,"acronym":26,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":82,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":193,"locationsCount":152},"100216664","efficacy-of-three-dimensional-transesophageal-echocardiography-for-percutaneous-device-closure-in-atrial-septal-defect-100216664","NCT02097758","Efficacy of Three Dimensional Transesophageal Echocardiography for Percutaneous Device Closure in Atrial Septal Defect","Inclusion Criteria:\n\n* Age ≥18 year-old\n* Susceptible indication for atrial septal defect closure\n* Potential candidate for device closure\n\nExclusion Criteria:\n\n* Poor candidate for device closure: multiple ASDs, ect\n* Other heart disease requiring open heart surgery","80 Years",{"count":182,"type":19},100,[84],"Background: Three-dimensional echocardiographic image for atrial septal defect (ASD) is useful for evaluation of defect size and shape. The investigators suggested optimal device size using three-dimensional transesophageal echocardiographic image and our formula in previous study.\n\nPurpose: In this study, the investigators seek to predict the correct device size and confirm the accuracy of the formula that we made before device closure in ASD patients.",[23,186],"Successful Device Closure","2025-02-05",{"date":189,"type":33},"2025-02-07",{"date":191,"type":4},"2014-03",{"date":121,"type":19},{"name":194,"class":124},"Asan Medical Center",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":202,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":152},"100534280","aware-registry-wearable-ecg-in-structural-heart-interventions-100534280","NCT06236776","AWARE Registry: Wearable ECG in Structural Heart Interventions","Arrhythmia Assessment in Structural Cardiac Interventions Using Wearable ECG Monitoring: AWARE Registry","Inclusion Criteria:\n\n* Adult ≥ 19 year-old\n* Patients who scheduled to perform percutaneous device closure for atrial septal defect or patent foramen ovale\n* Patients provided with the written, informed consent to participate in this study\n\nExclusion Criteria:\n\n* Patients who had paroxysmal, persistent, or chronic AF\n* Life expectancy \\\u003C 12 months\n* Subject who the investigator deems inappropriate to participate in this study","19 Years",{"count":204,"type":19},150,"This study is a multi-center (Sinchon Severance hospital \u002F Gangnam Severance hospital), prospective cohort observational study to patients who had undergone structural heart intervention including device closure for secundum type atrial septal defect or Patent foramen ovale. Transthoracic echocardiography will be performed before the procedure, immediately after, and at 6, 18, 30 months after the procedure. Wearable ECG monitoring (\\> 3 days) will be performed before the procedure or immediately after procedure. Demographic, laboratory, hemodynamic data during procedure, and non-invasive imaging dat are obtained.",[23,57],"2024-01-24",{"date":209,"type":33},"2024-02-01",{"date":211,"type":19},"2024-02",{"date":213,"type":19},"2028-06",{"name":215,"class":124},"Yonsei University",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":224,"enrollmentInfo":225,"targetDuration":227,"studyType":20,"phases":4,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":152},"100384660","canadian-adult-congenital-heart-disease-intervention-registry-100384660","NCT04288596","Canadian Adult Congenital Heart Disease Intervention Registry","The Canadian Registry for Adults With Congenital Heart Disease Interventions","C-ACHDiR","Inclusion Criteria:\n\n* participants must be 18 years or older referred for intervention for one of five ACHD conditions including diagnostic catheterization for complex ACHD patients (Tetralogy of Fallot, Fontan, and transposition of the great vessels, single ventricle, truncus arteriosus); transcatheter closure of atrial septal defects; transcatheter closure of patent foramen ovale; coarctation of aorta stenting, and percutaneous pulmonary valve implantation.\n\nExclusion Criteria:\n\n* participants below the age of 18\n* participants residing outside of Canada","110 Years",{"count":226,"type":19},9000,"10 Years","The ACHDi Registry study will create a foundational database for adult congenital heart disease interventions. This Pan-Canadian Registry will collect clinical and patient-reported information that will enable the evaluation of care processes and outcomes in five most common ACHDi interventions by enabling prospective and retrospective registry-based studies to answer important clinical practice and policy-relevant questions.",[23,57,230,231,232,233,234],"Tetralogy of Fallot","Fontan","Coarctation of Aorta","Transposition of Great Vessels","Percutaneous Pulmonary Valve Implantation","2020-02-27",{"date":237,"type":33},"2020-02-28",{"date":239,"type":19},"2020-04-01",{"date":241,"type":19},"2030-04-01",{"name":243,"class":124},"University Health Network, Toronto"]